Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04646109Phase 3Completed

Ivermectin for Severe COVID-19 Management

Role: collaborator

NCT00217815Phase 1Completed

Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer

Role: lead

NCT00217841Phase 3Completed

Aurograb and Vancomycin in MRSA Infection

Role: lead

All 3 trials loaded